B. Braun warehouse cited by Czech regulators

Czech Republic
Regulators in the Czech Republic have cited a B. Braun pharma warehouse.

Germany’s B. Braun has run afoul of regulators in Europe after an inspection last week of a warehouse in the Czech Republic found it was distributing products not on an approved list.  

According to a post by the European Medicines Agency, the site in Rudná was inspected Jan. 17 by Czech regulators. They said it was found the warehouse didn't "comply with the Good Distribution Practice requirements,” the agency said. According to the post, the agency suspended the authorization for the warehouse and ordered the “immediate” transfer of the drugs to another approved facility.   

Warehouse failings sometimes figure into regulatory issues. Last year the FDA issued a warning letter to a Chinese company that among many problems had a dirty warehouse. An Indian drugmaker was cited the before when inspectors found birds flying around the facility and a lizard was seen crawling around in a storage warehouse.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The Melsungen-based company has operations in 64 countries. Last summer it landed a $33 million loan from the International Finance Corporation (IFC), a member of the World Bank Group, to help fund the construction of a sterile injectables plant in Indonesia.

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.